A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

American Journal of Ophthalmology
T AungH M Lee

Abstract

To compare the intraocular pressure)-lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily. Sixty patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the morning, or unoprostone twice daily in the morning and evening. The study was double masked and followed a crossover design with two treatment periods of 1 month separated by a 3-week washout period. The intraocular pressure was measured at 9 AM and 5 PM on the baseline and day 28 visits, and at 9 AM on day 2 and day 14 visits of each treatment period. The 9 AM measurement was taken 2 hours and 13 hours after the last drop of unoprostone and latanoprost, and the 5 PM measurement was at 10 and 21 hours, respectively. The mean of the measurements was calculated. Safety parameters were also recorded. Fifty-six patients completed both treatment periods and had intraocular pressure data available for evaluation. After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 ...Continue Reading

References

Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·T TaniguchiY Kitazawa
Apr 29, 1998·Journal of the American Optometric Association·I B Gaddie, D W Bennett
Jul 31, 1998·American Journal of Ophthalmology·R D FechtnerR Warwar

❮ Previous
Next ❯

Citations

Sep 3, 2002·Survey of Ophthalmology·Remo SusannaYoshiaki Kitazawa
Sep 23, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Xiaohong LiXuyang Liu
Mar 27, 2004·Acta Ophthalmologica Scandinavica·William C StewartJessica Jenkins
Jan 4, 2006·American Journal of Ophthalmology·Robert J Noecker, John G Walt
Jan 1, 2004·American Journal of Ophthalmology·Robert S NoeckerUNKNOWN Bimatoprost/Latanoprost Study Group
Feb 22, 2012·Expert Opinion on Pharmacotherapy·Maurizio DigiuniLuca Rossetti
Jul 2, 2005·Expert Opinion on Emerging Drugs·Abbot F Clark, Iok-Hou Pang
Dec 10, 2002·American Journal of Ophthalmology·Henry D JampelUNKNOWN Latanoprost/Unoprostone Study Group
Jan 29, 2013·Prostaglandins & Other Lipid Mediators·Iwona DamsAndrzej Kutner
May 25, 2002·Journal of the American Geriatrics Society·Gary D NovackD William Molloy
Jan 1, 2012·Ophthalmology and Eye Diseases·Laura CrawleyLi Guo
Apr 3, 2003·Hospital Medicine·Ian Cunliffe
Jan 15, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Remo SusannaMarcelo L S Jordão
Mar 22, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Robert M Feldman
Aug 17, 2018·Journal of Glaucoma·Johan AspbergBoel Bengtsson
Jun 17, 2006·Journal of Glaucoma·Luca RossettiNicola Orzalesi
Apr 11, 2006·Japanese Journal of Ophthalmology·Yoko IkedaShigeru Kinoshita
Oct 27, 2018·Journal of Ophthalmology·Vlad DiaconitaCindy Hutnik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.